Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin

Back

ESC Premium Access

Real-world comparison of major bleeding and associated costs among treatment-naive non-valvular atrial fibrillation patients initiating apixaban or warfarin

Session: Poster session 3 - Anticoagulation in atrial fibrillation II

Topic: Atrial fibrillation (AF)

Speaker: Mr J. Trocio (New York, US)

Event: ESC Congress 2016

Congress Presentation

Add to my library

About the speaker

Mr Jeffrey Trocio

New York (United States of America)

0 follower

22 more presentations in this session

Is Aspirin monotherapy effective for stroke prevention in the real world? A UK cohort study evaluating the incidence of stroke in the absence of anticoagulation in atrial fibrillation (AF)

Speaker: Doctor E. Ridha (London, GB)

Access

Abstract

Slides

Poor anticoagulation control in warfarin treated atrial fibrillation patients with reduced renal function

Speaker: Doctor A. Nissen Bonde (Gentofte, DK)

Access

Abstract

Slides

In-hospital mortality, length of stay and costs of treating atrial fibrillation or flutter patients admitted for intracranial hemorrhage

Speaker: Doctor E. Nguyen (Storrs, US)

Access

Abstract

Slides

One-year permeability rate of left atrial appendage closure devices: high incidence of peridevice leak and lack of endothelialization

Speaker: Doctor G. Laugaudin (Montpellier, FR)

Access

Abstract

Net clinical benefit of rivaroxaban compared with warfarin in patients with atrial fibrillation

Speaker: Professor J. Piccini (Durham, US)

Access

Abstract

Slides

Access the full session

Poster session 3 - Anticoagulation in atrial fibrillation II

Speakers: Mr J. Trocio, Doctor E. Ridha, Doctor A. Nissen Bonde, Doctor E. Nguyen, Doctor G. Laugaudin...

Access

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources